SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-201044
Filing Date
2021-06-28
Accepted
2021-06-28 07:00:31
Documents
15
Period of Report
2021-06-26
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d197054d8k.htm   iXBRL 8-K 34772
2 EX-99.1 d197054dex991.htm EX-99.1 40290
6 GRAPHIC g197054dsp05.jpg GRAPHIC 19033
7 GRAPHIC g197054dsp05a.jpg GRAPHIC 2108
  Complete submission text file 0001193125-21-201044.txt   243511

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20210626.xsd EX-101.SCH 2885
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20210626_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20210626_pre.xml EX-101.PRE 11403
8 EXTRACTED XBRL INSTANCE DOCUMENT d197054d8k_htm.xml XML 3350
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 211049912
SIC: 2835 In Vitro & In Vivo Diagnostic Substances